Search

Your search keyword '"Margolin, David"' showing total 718 results

Search Constraints

Start Over You searched for: Author "Margolin, David" Remove constraint Author: "Margolin, David"
718 results on '"Margolin, David"'

Search Results

1. Enhancing Enrollment in Acute Stroke Trials: Current State and Consensus Recommendations

2. Anastomotic Construction

7. Presacral Bleeding

9. CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin

10. Perfusion assessment in laparoscopic left-sided/anterior resection (PILLAR II): a multi-institutional study.

15. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

17. sj-docx-1-mso-10.1177_20552173221142741 - Supplemental material for Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

19. Health-Care Economics

21. Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial

24. Health Care Economics

27. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

28. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

32. Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058

35. Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial

37. sj-pdf-1-tan-10.1177_1756286420982134 – Supplemental material for Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

40. CVN058, a 5-HT3 Receptor Antagonist, Shows Acute, Dose Dependent Improvement of Mismatch Negativity in a Double-Blind, Placebo-Controlled, Single Dose Cross-Over Study in Schizophrenia and Schizoaffective Disorder

41. Outcomes in Alemtuzumab-Treated Patients With Thyroid Adverse Events: 6-Year Pooled CARE-MS Data (1509)

42. Caveolin‐1‐driven membrane remodelling regulates hnRNPK‐mediated exosomal microRNA sorting in cancer

48. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

49. sj-pdf-1-mso-10.1177_2055217320972137 - Supplemental material for Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

Catalog

Books, media, physical & digital resources